Eisai

Eisai receives rights to antibody drug conjugate after Bristol ends collaboration

Love Employee Eisai (OTCPK:ESALF) has received the rights back to antibody drug conjugate farletuzumab ecteribulin (FZEC) after Bristol-Myers Squibb (NYSE:BMY) ended a strategic collaboration on the candidate. The Japanese pharma said it will accelerate development of the asset on its own. Eisai (ESAIY) has an ongoing phase 1 study inContinue Reading

Biogen, Eisai launch Alzheimer’s drug Leqembi in China (NASDAQ:BIIB)

In: Finance

Biogen (NASDAQ:BIIB) and its Japanese partner Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) breakthrough Alzheimer’s therapy, Leqembi (lecanemab), is now available in China, the companies announced late Thursday. Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody and said to be the only approved treatment shown to reduce the rate of disease progressionContinue Reading

Eisai receives rights to antibody drug conjugate after Bristol ends collaboration

Biogen, Eisai launch Alzheimer’s drug Leqembi in China (NASDAQ:BIIB)

How Rocket Companies modernized their data science solution on AWS | Amazon Web Services

AWS and DXC collaborate to deliver customizable, near real-time voice-to-voice translation capabilities for Amazon Connect | Amazon Web Services